Navigation Links
AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Date:6/3/2013

NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL).  Results from the study were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in patients with relapsed/refractory CLL and NHL. Secondary objectives included preliminary efficacy, including objective response rate (ORR), duration of response, time to progression, progression-free survival (PFS) and overall survival (OS). 

"The ABT-199 data underscore AbbVie's commitment to the development of treatments for some of the hardest-to-treat cancers like CLL and NHL," said Gary Gordon , M.D., divisional vice president, oncology clinical development, AbbVie. "Early trials of ABT-199 have shown the compound's potential in these hematological malignancies, which support the continuation of its clinical development program."

CLL Arm
As of April 2013, 56 patients have enrolled in the CLL arm of the Phase I trial, and 40 patients are currently active. Study participants were given a single oral dose of ABT-199, followed by six days without medication, before continuous once-daily dosing. Due to concerns over tumor lysis syndrome (TLS), the initial dose was reduced and daily dosing was modified. Single-agent activity was observed in the trial and warrants
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie
2. AbbVie to Present at Cowen and Company 33rd Annual Health Care Conference
3. AbbVie Declares Dividend and Announces Share Repurchase Program
4. JULABO USA Inc. Presents the New PRESTO® W91 and W92 Series of Highly Dynamic Temperature Control Systems
5. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
6. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
7. Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
8. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
9. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
10. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
11. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion ... consulting for global corporations operating in highly regulated ... its first annual Global User Group Conference, Xybion ... Philadelphia, Pennsylvania at the ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... novel combination of microscopy and data processing has given ... Laboratory an unprecedented look at the surface of a ... , The research team led by ORNL,s Zheng ... perovskite manganite, a complex material that exhibits dramatic magnetic ... behavior could benefit researchers who are interested in using ...
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... CBI is pleased to announce the full agenda for ... Access Congress, being held December 6-7, 2011 in Philadelphia, ... Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic ... Anchored by conference chairman, Robert Besthof, Vice President, ...
... -- Third ocular product partnered with Sanofi approved ... plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the ... Food and Drug Administration (FDA) has approved its Investigational ... development of UshStat ® , a novel gene-based treatment ...
... TRIANGLE PARK, N.C., Oct. 17, 2011 Max Neeman ... hemophilia trials according to the Clinical Trials Registry-India (CTRI). ... India, Max Neeman can boast supporting 80% of these ... International has established a team of experts specialized in ...
Cached Biology Technology:Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 3Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 4CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India 2
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
(Date:7/24/2014)... The planet,s current biodiversity, the product of 3.5 billion ... in the history of life. But it may be ... of scientific literature and analysis of data published in ... that the loss and decline of animals is contributing ... the planet,s sixth mass biological extinction event. , Since ...
(Date:7/24/2014)... terroir, meaning the microbial populations found on surfaces in ... the final flavor according to research published ahead of ... . This is the first time investigators have taken ... Many sake makers inoculate with both bacteria and yeast, ... of California, Davis, but he and his colleagues investigated ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2
... the University of Georgia, using glow-in-the-dark proteins and ... of a complex organelle in the bacterium that ... in new, precise detail the unique cell extension ... Mycoplasma pneumoniae. This structure, called a "terminal organelle," ...
... fruit flies, developmental biologists at the Kimmel Cancer Center ... a new way that genes are turned on and ... processes are at work in higher organisms, including mammals, ... understanding of a range of diseases, including childhood cancer. ...
... prevents the production of a critical blood-clotting protein. Treatments ... exist, may consist of risky blood transfusions or expensive ... be induced to begin producing these proteins, say by ... , Prof. Yair Reisner and Ph.D. student Anna Aronovich ...
Cached Biology News:UGA scientists unravel 'molecular inch-worm' structure of walking-pneumonia bacterium 2Jefferson researchers uncover new way nature turns genes on and off 2A transplant in time 2
CQCS kit for etra KR 4i , (other units)....
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
...
Biology Products: